Abstract
Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that singl......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
